I think double digit royalties on CYP-001 would mean GvHD and also the other diseases they may option.
Am very happy with the double digit, so 10-15% which is the upper end given Fuji will bear the costs after GvHD.
So, FUJI said their target is $US300m for GvHD alone by 2023.
This would mean annual royalties of A$40m PA to Cynata at lowest double digit (10%).
I said recently, this would make current cap look good for this one treatment alone. (on NPV). let alone the extra $60m milestones $$
Ann: Cynata & FUJIFILM Sign Strategic Partnership Agreement, page-15
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.29M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.0¢ | 27.5¢ | $36.56K | 130.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3702 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 17696 | 1 |
View Market Depth
| Last trade - 15.03pm 26/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |